GX Acquisition will ask shareholders to approves its request for a deadline extension to close a pending deal with Celularity, a clinical-stage biotechnology company
The SPAC said it wants to extend the deadline to July 31 from May 23. The vote date is set for May 14.
In addition to the approximately $292 million held in GX Acquisition Corp.’s trust account (assuming no stockholder redemptions), a group of existing and other institutional investors have committed to participate in a concurrent equity financing through the sale of approximately $80 million of GX Acquisition Class A common stock at $10 per share. Read more.
